PLC/CAMK IV-NF-κB involved in the receptor for advanced glycation end products mediated signaling pathway in human endothelial cells

Molecular and Cellular Endocrinology

Volumn 320, Issue 1-2, 2010, Pages 111-117

  You, Jie ^a   Peng, Wei ^a   Lin, Xu ^a   Huang, Qing Ling ^a   Lin, Jian Yin ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Advanced glycation end products; Ca2+ signaling pathway; Diabetic vascular complications; Inflammation; NF B

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; ADVANCED GLYCATION END PRODUCT; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE IV; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; PHOSPHOLIPASE C BETA1; PHOSPHOLIPASE C BETA4; RNA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CALCIUM SIGNALING; CELL VIABILITY; CONTROLLED STUDY; DNA MICROARRAY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PLASMID; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UMBILICAL VEIN; UPREGULATION;

CALCIUM; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 4; CELL LINE; CELL SURVIVAL; ENDOTHELIAL CELLS; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; GENES, DOMINANT; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INTERLEUKIN-6; INTRACELLULAR SPACE; NF-KAPPA B; RECEPTORS, IMMUNOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, ANTISENSE; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; TYPE C PHOSPHOLIPASES;

EID: 77949571438     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2010.01.036     Document Type: Article

References (46)

1. Aleshin A., Ananthakrishnan R., Li Q., Rosario R., Lu Y., Qu W., Song F., Bakr S., Szabolcs M., D'Agati V., Liu R., Homma S., Schmidt A.M., Yan S.F., Ramasamy R. RAGE modulates myocardial injury consequent to LAD infarction via impact on JNK and STAT signaling in a murine model. Am. J. Physiol. Heart Circ. Physiol. 2008, 294:1823-1832.
2. Bonke V.T., Thorpe S.R., Coughlan M.T., Fukami K., Yap F.Y., Sourris K.C., Penfold S.A., Bach L.A., Cooper M.E., Forbes J.M. Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-α dependent pathway. Diabetes 2008, 57:460-469.
3. Bierhaus A., Illmer T., Kasper M., Luther T., Quehenberger P., Tritschler H., Wahl P., Ziegler R., Müller M., Nawroth P.P. Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation 1997, 96:2262-2271.
4. Bierhaus A., Schiekofer S., Schwaninger M., Andrassy M., Humpert P.M., Chen J., Hong M., Luther T., Henle T., Klöting I., Morcos M., Hofmann M., Tritschler H., Weigle B., Kasper M., Smith M., Perry G., Schmidt A.M., Stern D.M., Häring H.U., Schleicher E., Nawroth P.P. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 2001, 50:2792-2808.
5. Bucala R., Tracey K.J., Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J. Clin. Invest. 1991, 87:432-438.
6. Bucciarelli L.G., Wendt T., Qu W., Lu Y., Lalla E., Rong L.L., Goova M.T., Moser B., Kislinger T., Lee D.C., Kashyap Y., Stern D.M., Schmidt A.M. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002, 106:2827-2835.
7. Brownlee M., Cerami A., Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med. 1988, 318:1315-1321.
8. David K.C., Scott R.H., Nixon G.F. Advanced glycation end products induce a proliferative response in vascular smooth muscle cells via altered calcium signaling. Biochem. Pharmacol. 2008, 76:1110-1120.
9. Enslen H., Tokumitsu H., Stork P.J., Davis R.J., Soderling T.R. Regulation of mitogen-activated protein kinases by a calcium/calmodulin-dependent protein kinase cascade. Proc. Natl. Acad. Sci. 2006, 93:10803-10808.
10. Figarola J.L., Scott S., Loera S., Xi B., Synold T., Weiss L., Rahbar S. Prevention of early renal disease, dyslipidaemia and lipid peroxidation in STZ-diabetic rats by LR-9 and LR-74, novel AGE inhibitors. Diabetes Metab. Res. Rev. 2005, 21:533-544.
11. Genuth S., Sun W., Cleary P., Sell D.R., Dahms W., Malone J., Sivitz W., Monnier V.M. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 2005, 54:3103-3111. DCCT Skin Collagen Ancillary Study Group.
12. Gu L., Hagiwara S., Fan Q., Tanimoto M., Kobata M., Yamashita M., Nishitani T., Gohda T., Ni Z., Qian J., Horikoshi S., Tomino Y. Role of receptor for advanced glycation end-products and signalling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes. Nephrol. Dial. Transplant. 2006, 21:299-313.
13. Harja E., Bu D.X., Hudson B.I., Chang J.S., Shen X., Hallam K., Kalea A.Z., Lu Y., Rosario R.H., Oruganti S., Nikolla Z., Belov D., Lalla E., Ramasamy R., Yan S.F., Schmidt A.M. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. J. Clin. Invest. 2008, 118:183-194.
14. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A.W. 10-Year follow-up of intensive glucose control in Type 2 Diabetes. N. Engl. J. Med. 2008, 359:1577-1589.
15. Howe C.J., Lahair M.M., McCubrey J.A., Franklin R.A. Redox regulation of the calcium/calmodulin-dependent protein kinases. J. Biol. Chem. 2004, 279:44573-44581.
16. 2+/calmodulin kinase type IV/Gr. J. Exp. Med. 1996, 184:101-112.
17. Hudson B.I., Kalea A.Z., Del M.A.M., Harja E., Boulanger E., D'Agati V., Schmidt A.M. Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J. Biol. Chem. 2008, 283:34457-34468.
18. Ishihara K., Tsutsumi K., Kawane S., Nakajima M., Kasaoka T. The receptor for advanced glycation end-products (RAGE) directly binds to ERK by a D-domain-like docking site. FEBS Lett. 2003, 550:107-113.
19. 2+/calmodulin-dependent protein kinase IV stimulates nuclear factor-kappa B transactivation via phosphorylation of the p65 subunit. J. Biol. Chem. 2001, 276:20005-20010.
20. 2+-dependent regulation of rho GTPases triggers turning of nerve growth cones. J. Neurosci. 2005, 25:2338-2347.
21. Lander H.M., Tauras J.M., Ogiste J.S., Hori O., Moss R.A., Schmidt A.M. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J. Biol. Chem. 1997, 272:17810-17814.
22. Li J., Schmidt A.M. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J. Biol. Chem. 1997, 272:16498-164506.
23. Means A.R. Regulatory cascades involving calmodulin-dependent protein kinases. Mol. Endocrinol. 2000, 14:4-13.
24. Marsche G., Semlitsch M., Hammer A., Frank S., Weigle B., Demling N., Schmidt K., Windischhofer W., Waeg G., Sattler W., Malle E. Hypochlorite-modified albumin colocalizes with RAGE in the artery wall and promotes MCP-1 expression via the RAGE-Erk1/2 MAP-kinase pathway. FASEB J. 2007, 21:1145-1152.
25. Nathan D.M., Cleary P.A., Backlund J.Y., Genuth S.M., Lachin J.M., Orchard T.J., Raskin P., Zinman B. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 2005, 353:2643-2653. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group.
26. Neeper M., Schmidt A.M., Brett J., Yan S.D., Wang F., Pan Y.C., Elliston K., Stern D., Shaw A. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. 1992, 267:14998-15004.
27. Patel M.K., Lymn J.S., Clunn G.F., Hughes A.D. Thrombospondin-1 is a potent mitogen and chemoattractant for human vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 1997, 17:2107-2114.
28. Petrova R., Yamamoto Y., Muraki K., Yonekura H., Sakurai S., Watanabe T., Li H., Takeuchi M., Makita Z., Kato I., Takasawa S., Okamoto H., Imaizumi Y., Yamamoto H. Advanced glycation endproduct-induced calcium handling impairment in mouse cardiac myocytes. J. Mol. Cell. Cardiol. 2002, 34:1425-1431.
29. Racioppi L., Means A.R. Calcium/calmodulin-dependent kinases IV in immune and inflammatory responses: noval routes for an ancient traveler. Trends Immunol. 2008, 29:600-606.
30. Rhee S.G. Regulation of phosphoinositide-specific phospholipase C. Annu. Rev. Biochem. 2001, 70:281-312.
31. Ramasamy R., Yan S.F., Herold K., Clynes R., Schmidt A.M. Receptor for advanced glycation end products: fundamental roles in the inflammatory response: winding the way to the pathogenesis of endothelial dysfunction and atherosclerosis. Ann. N Y Acad. Sci. 2008, 1126:7-13.
32. Rashid G., Benchetrit S., Fishman D., Bernheim J. The effects of advanced glycation end products (AGEs) on endothelial cell nitric oxide synthase and Tumor Necrosis Factor-α expression are AGE receptor dependent. Ann. N Y Acad. Sci. 2005, 1043:934-987.
33. Sakaguchi T., Yan S.F., Yan S.D., Belov D., Rong L.L., Sousa M., Andrassy M., Marso S.P., Duda S., Arnold B., Liliensiek B., Nawroth P.P., Stern D.M., Schmidt A.M., Naka Y. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J. Clin. Invest. 2003, 111:959-972.
34. (2+) oscillations in eggs and embryo development. Development 2002, 129:3533-3544.
35. Schmidt A.M., Hori O., Chen J.X., Li J.F., Crandall J., Zhang J., Cao R., Yan S.D., Brett J., Stern D. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J. Clin. Invest. 1995, 96:1395-1403.
36. Schmidt A.M., Yan S.D., Yan S.F., Stern D.M. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J. Clin. Invest. 2001, 108:949-955.
37. Schiekofer S., Andrassy M., Chen J., Rudofsky G., Schneider J., Wendt T., Stefan N., Humpert P., Fritsche A., Stumvoll M., Schleicher E., Häring H.U., Nawroth P.P., Bierhaus A. Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK, and nuclear factor kappaB in PBMCs. Diabetes 2003, 52:621-633.
38. Shanmugam N., Kim Y.S., Lanting L., Natarajan R. Regulation of cyclooxygenase-2 expression in monocytes by ligation of the receptor for advanced glycation end products. J. Biol. Chem. 2003, 278:34834-34844.
39. Stern D., Yan S.D., Yan S.F., Schmidt A.M. Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv. Drug Deliv. Rev. 2002, 54:1615-1625.
40. Talmor Y., Golan E., Benchetrit S., Bernheim J., Klein O., Green J., Rashid G. Calcitriol blunts the deleterious impact of advanced glycation end products on endothelial cells. Am. J. Physiol. Renal Physiol. 2008, 294:F1059-F1064.
41. Tanaka N., Yonekura H., Yamagishi S., Fujimori H., Yamamoto Y., Yamamoto H. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17 beta-estradiol through Sp-1 in human vascular endothelial cells. J. Biol. Chem. 2000, 275:25781-25790.
42. Xu B., Chibber R., Ruggiero D., Kohner E., Ritter J., Ferro A. Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. FASEB J. 2003, 17:1289-1291.
43. Xu D., Kyriakis J.M. Phosphatidylinositol 3′-kinase-dependent activation of renal mesangial cell Ki-Ras and ERK by advanced glycation end products. J. Biol. Chem. 2003, 278:39349-39355.
44. Yamagishi S., Fujimori H., Yonekura H., Yamamoto Y., Yamamoto H. Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells. Diabetologia 1998, 41:1435-1441.
45. Yamagishi S., Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr. Pharm. Des. 2005, 11:2279-2299.
46. Yang Y.L., Chuang L.Y., Guh J.Y., Liu S.F., Hung M.Y., Liao T.N., Huang Y.L. Thrombospondin-1 mediates distal tubule hypertrophy induced by glycated albumin. Biochem. J. 2004, 379:89-97.